Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide maps of transcription in Multiple Myeloma cells treated with FHND004 or FHND008

ABSTRACT: Genome-wide maps of transcription in Multiple Myeloma cells treated with FHND004 or FHND008

PROVIDER: PRJNA925161 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23111100_1.fastq.gz	Fastqsanger.gz
	SRR23111100_2.fastq.gz	Fastqsanger.gz
	SRR23111101_1.fastq.gz	Fastqsanger.gz
	SRR23111101_2.fastq.gz	Fastqsanger.gz
	SRR23111102_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Genome-wide maps of transcription in Multiple Myeloma cells treated with FHND004 or FHND008

Project description:FHND004 and FHND008 are newly synthesized epidermal growth factor receptor (EGFR) inhibitor for the treatment of non-small cell lung cancer (NSCLC), they were obtained on the basis of AZD9291. We found that FHND004 and FHND008 had a strong inhibitory effect on the proliferation of multiple myeloma cells in vitro. Genome-wide maps of transcription showed different genes change in Multiple Myeloma cells after 4μM FHND004 or FHND008 intervention.

2024-04-03 | GSE223166 | GEO

Multiple myeloma

Project description:Multiple myeloma

| PRJNA515992 | ENA

Multiple Myeloma cells

Project description:Multiple Myeloma cells

| PRJNA800411 | ENA

Genome-wide maps of transcription in PNPO overexpression(OE) and wildtype(WT) cells in Multiple Myeloma

Project description:Genome-wide maps of transcription in PNPO overexpression(OE) and wildtype(WT) cells in Multiple Myeloma

| PRJNA750421 | ENA

Genome-wide maps of transcription in GART overexpression(OE) and wildtype(WT) cells in Multiple Myeloma

Project description:Genome-wide maps of transcription in GART overexpression(OE) and wildtype(WT) cells in Multiple Myeloma

| PRJNA923677 | ENA

Jumonji Demethylase Inhibitor GSK-J4 treated Multiple Myeloma JJN3 and RPMI

Project description:Analysis of Multiple Myeloma Cell lines JJN-3 and RPMI gene expression following treated with GSK-J4 or Bortezomib

2016-08-21 | GSE60600 | GEO

Huma Multiple Myeloma Cell line, AMO1, treated with NCP26, LC-MSMS analysis

Project description:The human multiple myeloma cell line, AMO1, was treated with NCP26, an ATP-competitive EPRS inhibitor, and a total proteome-wide analysis was performed to determine the effect of NCP26 treatment on protein dynamics.

2023-03-11 | PXD029453 | Pride

Proteogenomic landscape of multiple myeloma

Project description:Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, multiple myeloma remains incurable and better risk stratification as well as new therapies are therefore highly needed. The proteome of multiple myeloma has not been systematically assessed before and holds the potential to uncover additional insight into disease biology and improved prognostic models. Here, we provide a comprehensive multi-omics analysis including deep tandem mass tag (TMT)-based quantitative global (phospho)proteomics, RNA sequencing and nanopore DNA sequencing of 138 primary patient-derived plasma cell malignancies encompassing treatment-naive multiple myeloma patients treated in clinical trials, plasma cell leukemia, and the premalignancy monoclonal gammopathy of undetermined significance (MGUS), as well as healthy controls. We found that the (phospho)proteome of malignant plasma cells is highly deregulated as compared to healthy plasma cells and is both defined by chromosomal alterations and extensive post-transcriptional regulation. A protein signature was identified that is associated with aggressive disease and more predictive for outcome than cytogenetic-based risk assessment in newly diagnosed multiple myeloma. Integration with functional genetics and single-cell sequencing revealed generally and genetic subtype-specific deregulated proteins and pathways in plasma cell malignancies that include novel potential targets for (immuno)therapies. These findings provide new insights in the biology of multiple myeloma and will be a unique resource for investigating new therapeutic approaches.

2024-07-09 | PXD043580 | Pride

Proteogenomic landscape of multiple myeloma

Project description:Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, multiple myeloma remains incurable and better risk stratification as well as new therapies are therefore highly needed. The proteome of multiple myeloma has not been systematically assessed before and holds the potential to uncover additional insight into disease biology and improved prognostic models. Here, we provide a comprehensive multi-omics analysis including deep tandem mass tags (TMT)-based quantitative global (phospho)proteomics, RNA sequencing and nanopore DNA sequencing of 138 primary patient-derived plasma cell malignancies encompassing treatment-naive multiple myeloma patients treated in clinical trials, plasma cell leukemia, and the premalignancy monoclonal gammopathy of undetermined significance (MGUS), as well as healthy controls. We found that the (phospho)proteome of malignant plasma cells is highly deregulated as compared to healthy plasma cells and is both defined by chromosomal alterations and extensive post-transcriptional regulation. A protein signature was identified that is associated with aggressive disease and more predictive for outcome than cytogenetic-based risk assessment in newly diagnosed multiple myeloma. Integration with functional genetics and single-cell sequencing revealed generally and genetic subtype-specific deregulated proteins and pathways in plasma cell malignancies that include novel potential targets for (immuno)therapies. These findings provide new insights in the biology of multiple myeloma and will be a unique resource for investigating new therapeutic approaches.

2024-07-09 | PXD038437 | Pride

Transcriptome analysis of untreated multiple myeloma cells and multiple myeloma cells treated with T6, F2, I3C and DIM

Project description:Transcriptome analysis of untreated multiple myeloma cells and multiple myeloma cells treated with T6, F2, I3C and DIM

| PRJNA782497 | ENA